Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. News
  7. Summary
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sino Biopharmaceutical Limited Announces Lenvatinib Mesilate Capsule Has Obtained Drug Registration Certificate Granted by the National Medical Products Administration of the Prc

07/26/2021 | 05:12am EDT

The Board of Directors of Sino Biopharmaceutical Limited (the ‘Company’, together with its subsidiaries, the ‘Group’) announces that ‘Lenvatinib Mesilate Capsule’, a liver cancer treatment drug developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the PRC. This product was filed as a Chemicals Category 4 drug, and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, being the first generic drug of its kind that has obtained approval for drug registration in China. The approved indication is: for the treatment of unresectable hepatocellular carcinoma patients who have not received systemic treatment in the past. Lenvatinib is a multiple tyrosine kinase receptors (RTK) inhibitor, which can inhibit the kinase activity of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4), and also inhibit fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor KIT and RET fusion genes, thereby inhibiting tumor angiogenesis and tumor progression. Lenvatinib mesilate was the only drug that had obtained positive results in phase III clinical studies in the field of first-line targeted therapy for liver cancer in the past decade. Clinical data showed that the efficacy of lenvatinib mesilate was particularly impressive in the Chinese patient subgroup compared to the total global population. Lenvatinib mesilate has been adopted as the first-line drug for the treatment of middle-late stage liver cancer in countries including China, Japan, and the United States. According to statistics, there are 466,000 new liver cancer patients in China each year, accounting for more than half of the global incidence (cited from: Cancer Statistics in China, 2015). Currently, only the brand-name drug of lenvatinib mesilate capsule is available in the domestic market, so there is a wide market potential. The approval for the launch of lenvatinib mesilate capsule developed by the Group will further improve the Group's anti-tumor product line layout and help reduce the economic burden of liver cancer patients in China.


© S&P Capital IQ 2021
All news about SINO BIOPHARMACEUTICAL LIMITED
09/13SINO BIOPHARMACEUTICAL LIMITED : Ex-dividend day for quarterly dividend
FA
09/02SINO BIOPHARMACEUTICAL : Receives Registration Approval for Cancer Treatment in China
MT
09/02SINO BIOPHARMACEUTICAL : Gets Registration Approval for Hepatitis Treatment in China
MT
09/01Hong Kong Hang Seng Rises 0.6%, Led by Tech Sector
MT
09/01Sino Biopharmaceutical Limited Announces Sofosbuvir Tablets Obtains Drug Registration C..
CI
09/01Sino Biopharmaceutical Limited's Lenvatinib Mesilate Capsule Obtains Drug Registration ..
CI
08/31Sino Biopharmaceutical Limited Announces Second Ordinary Interim Dividend for the Finan..
CI
08/31Sino Biopharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30..
CI
08/19Hong Kong Hang Seng Down 2.1% on Beijing Regulatory Outlook
MT
08/18Sino Biopharmaceutical Limited Provides Earnings Guidance for the Six Months Ended 30 J..
CI
More news
Analyst Recommendations on SINO BIOPHARMACEUTICAL LIMITED
More recommendations
Financials
Sales 2021 34 305 M 4 406 M 4 406 M
Net income 2021 10 387 M 1 334 M 1 334 M
Net cash 2021 10 050 M 1 291 M 1 291 M
P/E ratio 2021 12,3x
Yield 2021 2,06%
Capitalization 117 B 15 019 M 15 019 M
EV / Sales 2021 3,12x
EV / Sales 2022 2,48x
Nbr of Employees 24 443
Free-Float 52,3%
Chart SINO BIOPHARMACEUTICAL LIMITED
Duration : Period :
Sino Biopharmaceutical Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINO BIOPHARMACEUTICAL LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 6,23 HKD
Average target price 10,65 HKD
Spread / Average Target 70,9%
EPS Revisions
Managers and Directors
Yi Li Chief Executive Officer & Executive Director
Theresa Tse Chairman
Hsuan Tse General Manager-Information Management
Wei Nong Ye General Manager-Research & Development
Mao Li Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED-16.93%15 019
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972